In Vitro Antibody Assays using Therapeutic Antibodies

Selection of the best cellular model for your study among:

  • Various hematological cancer cell lines (AML, DLBCL, MM, MCL…)
  • Unique proprietary panel of multiple myeloma cell lines (n=25)
  • Primary samples from patients with hematological malignancies (Multiple Myeloma, Non-Hodgkin Lymphoma, Acute and Chronic Leukemia…)
  • Access to general information, genomic and clinical data from samples (age, gender, subtypes, gene expression profile, mutations, FISH, epigenetic data, treatment and response…)
  • Access to longitudinal samples at diagnosis, end of treatment and relapses.


In Vitro assays to investigate the direct and indirect cell-mediated cytotoxicity

  • Cell viability assays, Drug combinations
  • ADCC assays using PBMC or NK cells from patients or healthy donor
  • Immunophenotyping and Monitoring of B, T and NK cells subtypes using multiparameter flow cytometry
  • Hematological cancer cell lines
  • Primary cells from patients with hematologic malignancies
  • Multiparameter flow cytometry (13 colors)
  • Cell viability assays
  • Drug combinaisons using conventional of target treatments
  • In vitro assessment of antibodies autologous cytotoxicity
  • In vitro assessment of antibodies heterologous cytotoxicity
  • Customized services on request
  • A Final Report
  • Raw and Treated data

Immunogenomic Analysis

We propose a creating comprehensive portrait of the tumor cells and their microenvironment using RNA and DNA sequencing data from patients with various hematological cancers. Also, we propose a development of a cloud-based analytic platform to analyse and visualize your immunogenomic data.

Transcriptomic characterization of immune activities within tumor micro-environment

  • Tumor Immunogenicity
  • Tumor inflammatory signature
  • Anti-tumor immune activities
  • Inhibitory Immune Signaling
  • Immune infiltration (deconvolution of heterogeneous samples)

Identification of relevant mutations and Tumor Mutational Burden (TMB)

  • Mutated oncogenic pathways
  • Mutated genes and durg interaction
  • Estimation of Tumor Mutational load

TCR profiling using NGS

  • Identification of T cell clones by analyzing CDR3 region
  • Visualization of the number of clones and their proportion
  • Calculation of Shannon entropy (Clonal diversity)
immunogenomic analysis
  • Access to large cohorts of RNAseq data from primary samples already sequenced (MM, LLC, DLBCLs, DLBCLs, FL, MCL, ZML)
  • Access to WESseq data of primary samples already sequenced (MM, LLC, DLBCLs, DLBCLs, FL, MCL, ZML)
  • Access to DNA and RNA of a large panel of primary samples (longitudinal samples, MM, LLC, DLBCLs, DLBCLs, FL, MCL, ZML, AML, ALL…)
  • Possibilities to perform sequencing of your samples or after treatment studies
  • RNA/DNA extraction
  • RNAseq, WES, target sequencing
  • Immune composition
  • Immune activities
  • TCR profiling
  • HLA typing
  • Biomarkers identification
  • Customized services
  • A final report
  • Raw and aligned data
  • A cloud-based analytic platform to analyze and visualize the immunogenomic data